Entrada Therapeutics, Inc.
TRDA
$7.46
$0.010.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 898.00K | 875.00K | 1.30M | 1.61M | 1.95M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 898.00K | 875.00K | 1.30M | 1.61M | 1.95M |
| Cost of Revenue | 35.37M | 33.05M | 32.26M | 38.36M | 37.88M |
| Gross Profit | -34.47M | -32.18M | -30.96M | -36.75M | -35.93M |
| SG&A Expenses | 10.49M | 10.12M | 9.35M | 10.30M | 10.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.86M | 43.18M | 41.61M | 48.67M | 48.80M |
| Operating Income | -44.96M | -42.30M | -40.31M | -47.05M | -46.85M |
| Income Before Tax | -42.73M | -39.68M | -39.07M | -43.48M | -42.93M |
| Income Tax Expenses | 35.00K | 38.00K | 92.00K | 654.00K | 178.00K |
| Earnings from Continuing Operations | -42.76M | -39.72M | -39.16M | -44.13M | -43.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.76M | -39.72M | -39.16M | -44.13M | -43.10M |
| EBIT | -44.96M | -42.30M | -40.31M | -47.05M | -46.85M |
| EBITDA | -44.12M | -41.50M | -39.42M | -45.82M | -45.82M |
| EPS Basic | -1.01 | -0.95 | -0.94 | -1.06 | -1.04 |
| Normalized Basic EPS | -0.63 | -0.59 | -0.56 | -0.66 | -0.65 |
| EPS Diluted | -1.01 | -0.95 | -0.94 | -1.06 | -1.04 |
| Normalized Diluted EPS | -0.63 | -0.59 | -0.56 | -0.66 | -0.65 |
| Average Basic Shares Outstanding | 42.22M | 41.84M | 41.60M | 41.46M | 41.34M |
| Average Diluted Shares Outstanding | 42.22M | 41.84M | 41.60M | 41.46M | 41.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |